A Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Abituzumab for patients with SSc-ILD taking mycophenolate
Sponsor: Merck EMD Serono
Enrolling: Male and Female Patients
Study Length: 2 Years
IRB Number: AAAQ6154
U.S. Govt. ID: NCT02745145
Contact: Rachel Broderick: 212-342-2713 / rb3173@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine the efficacy and safety of abituzumab in subjects withsystemic sclerosis-associated interstitial lung disease (SSc-ILD).Abituzumab is an investigational drug that is being evaluated for the treatment of patients withsystemic sclerosis (SSc)-associated interstitial lung disease (SSc-ILD). Systemic sclerosis, alsoknown as scleroderma, is an autoimmune disease that can affect many organs, including the stomach,intestines, heart, and lungs. In general, SSc causes hardening of the skin and organs. SSc-ILD involves damage to lung tissue and can cause difficulty breathing and worsening lung function.Investigational means that the study drug has not been approved by any health authority (government authorities) such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA), and is still being tested for safety and effectiveness. Information gathered from this study will be sent to the various health authorities. The main purpose of this study is to find out if the study drug can improve the function of the lungs inpatients with SSc-ILD.
This study is closed
Elana Bernstein, MD
Do You Qualify?
Do you have systemic sclerosis / scleroderma? Yes No
Are you taking mycophenolate (MMF or MPS)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Rachel Broderick